A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma

ClinicalTrials.gov ID: NCT00848926

Public ClinicalTrials.gov record NCT00848926. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a single-arm, open-label, multicenter, pivotal clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory Hodgkin lymphoma.

Study identification

NCT ID: NCT00848926
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Seagen Inc.; Industry
Enrollment: 102 participants

Conditions and interventions

Conditions

Disease, Hodgkin

Interventions

brentuximab vedotin Drug

Drug

Eligibility (public fields only)

Age range: 12 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 31, 2009
Primary completion: Jul 31, 2010
Completion: Apr 30, 2015
Last update posted: Mar 12, 2017

2009 – 2015

United States locations

U.S. sites: 19
U.S. states: 14
U.S. cities: 18

Facility	City	State	ZIP	Site status
University of Alabama at Birmingham	Birmingham	Alabama	35294-3300	—
City of Hope National Medical Center	Duarte	California	91010-3000	—
University of California at Los Angeles	Los Angeles	California	90095	—
Stanford University Medical Center	Palo Alto	California	94305	—
Rocky Mountain Cancer Center	Denver	Colorado	80218	—
Georgetown University	Washington D.C.	District of Columbia	20007	—
University of Miami	Miami	Florida	33136	—
Loyola University Medical Center Cardinal Bernardin Cancer Center	Maywood	Illinois	60153	—
Karmanos Cancer Institute	Detroit	Michigan	48201	—
Mayo Clinic Rochester	Rochester	Minnesota	55905	—
Washington University School of Medicine	St Louis	Missouri	63110	—
Weill Cornell Medical College	New York	New York	10021	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
University of Rochester Medical Center	Rochester	New York	14642	—
Ohio State University	Columbus	Ohio	43210	—
Oregon Health & Science University	Portland	Oregon	97239	—
Baylor Sammons Cancer Center	Dallas	Texas	75246	—
University of Texas MD Anderson Cancer Center	Houston	Texas	77030-4009	—
University of Washington	Seattle	Washington	98109	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00848926, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 12, 2017 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00848926 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →